Industry News
Pharmaceutical Industry News
Italy’s antitrust agency, the…
Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over claims it is abusing its market position regarding a test for its multiple sclerosis drug Tysabri (natalizumab).
Eli Lilly has successfully…
Eli Lilly has successfully challenged Noom’s “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.
A Flood of New, Deadlier Drugs
“The Daily” speaks with Azam Ahmed, a New York Times international investigative correspondent, about his latest piece on the synthetic drug crisis.
After a formal dispute resolution…
After a formal dispute resolution process that followed three prior rejections, the FDA has decided that Outlook's eye drug candidate Lytenava has shown evidence of effectiveness.
A Deadly Drug Cocktail Made of Paper Is Killing Inmates
The Daily host Natalie Kitroeff speaks with New York Times investigative reporter Azam Ahmed about his reporting about a deadly paper-based drug making its way through Cook County Jail.
A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?
Lenacapavir, which protects people from H.I.V. infection with twice-yearly shots, is arriving in a country where the health system has been hollowed out by American aid cuts.
Eli Lilly to Buy 3 Vaccine Developers
The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other pathogens.
The potential $7 billion buyout…
The potential $7 billion buyout deal in the radiopharmaceutical space could be weeks away, Bloomberg reported, citing people familiar with the matter.
Korea’s SK bioscience has signed…
Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company’s chickenpox vaccine SKYVaricella.
More than three years after Gilead…
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S.
Inside the Evolution of Synthetic Drugs
Natalie Kitroeff from “The Daily” speaks with Azam Ahmed, a New York Times international investigative correspondent, about his latest piece on the synthetic drug crisis.
Two years after launching its…
Two years after launching its “More To Parkinson’s” campaign with actor Ryan Reynolds, Acadia Pharmaceuticals is asking Reynolds to suit up once again as it broadens the project.
Niowave has broken ground on a $75…
Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to employ 70 people.
The layoffs at AbbVie’s Irvine,…
The layoffs at AbbVie's Irvine, California, location will take effect on July 20, according to a recent WARN notice.
Less than a month after an FDA…
Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy
AbbVie’s 85 layoffs are tied to…
AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at its U.S. HQ in New Jersey.
A three-way battle among TROP2…
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo's Datroway became the first to cross the FDA's finish line.
AbbVie and GSK have surged up the…
AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards.
Merck & Co. and…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking licensing deals in China, experts
Tyra Biosciences has partnered…
Tyra Biosciences has partnered with a patient advocacy group to create an awareness day for upper tract urothelial cancer, a rare tumor type its lead drug candidate targets.